World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
54
Citations
11661
World Ranking
15532
National Ranking
6478

Youli Zu publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Youli Zu sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 413 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 848 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 949 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 840 scientists 207–216 publications: 733 scientists 217–226 publications: 708 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 417 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 196 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 59 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 220 publications — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Youli Zu D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Youli Zu sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 316 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 899 scientists 52–53 D-Index: 1,025 scientists 54–55 D-Index: 1,149 scientists 56–57 D-Index: 1,235 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,162 scientists 62–63 D-Index: 1,130 scientists 64–65 D-Index: 1,031 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 714 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 71 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 54 D-Index — 22nd percentile

22% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Youli Zu is affiliated with Houston Methodist in the United States and has a research focus spanning the fields of medicine and biochemistry, genetics, and molecular biology. Their scholarly output includes numerous contributions to molecular biology, pathology and forensic medicine, oncology, genetics, and hematology.

Their research addresses several specialized topics, including:

  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Advanced biosensing and bioanalysis techniques
  • CAR-T cell therapy research
  • Acute Myeloid Leukemia Research
  • Cancer Genomics and Diagnostics
  • RNA Interference and Gene Delivery

They have published in various scientific venues, with frequent appearances in:

  • UNC Libraries
  • Blood
  • Nature Communications
  • Journal of Hematology & Oncology
  • Journal for ImmunoTherapy of Cancer

Recent papers by Youli Zu include:

  • Neutralizing Aptamers Block S/RBD-ACE2 Interactions and Prevent Host Cell Infection, 2021, Angewandte Chemie International Edition
  • MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma, 2022, Nature Communications
  • MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma, 2020, Blood
  • XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53, 2020, Journal of Hematology & Oncology
  • Oligonucleotide aptamers for pathogen detection and infectious disease control, 2021, Theranostics

The scientist has collaborated frequently with several coauthors, notably:

  • Alexandar Tzankov
  • Govind Bhagat
  • Zijun Y. Xu-Monette
  • April Chiu
  • Eric D. Hsi

Best Publications

  • Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy

    Hongguang Sun;Xun Zhu;Patrick Y Lu;Roberto R Rosato

  • MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

    Shimin Hu;Zijun Y. Xu-Monette;Alexander Tzankov;Tina Green

  • Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins

    Catherine M. Bollard;Catherine M. Bollard;Stephen Gottschalk;Stephen Gottschalk;Vicky Torrano;Vicky Torrano;Oumar Diouf;Oumar Diouf

  • Detecting Circulating Tumor Cells: Current Challenges and New Trends

    Bin Hong;Youli Zu

  • p38 Mitogen-Activated Protein Kinase Activation Is Required for Human Neutrophil Function Triggered by TNF-α or FMLP Stimulation

    You Li Zu;Jiafan Qi;Annette Gilchrist;Gustavo A. Fernandez

  • Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

    Zijun Y. Xu-Monette;Lin Wu;Carlo Visco;Yu Chuan Tai

  • A Highlight of recent advances in aptamer technology and its application

    Hongguang Sun;Youli Zu

  • Ischemic preconditioning triggers the activation of MAP kinases and MAPKAP kinase 2 in rat hearts.

    Nilanjana Maulik;Masazumi Watanabe;You Li Zu;Chi Kuang Huang

  • Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL Rituximab-CHOP Consortium Program Study

    C Visco;Y Li;Z Y Xu-Monette;R N Miranda

  • Ischemic preconditioning triggers tyrosine kinase signaling: a potential role for MAPKAP kinase 2

    Nilanjana Maulik;Tetsuya Yoshida;You Li Zu;Motoaki Sato

  • Multiplexed volumetric bar-chart chip for point-of-care diagnostics

    Yujun Song;Yuanqing Zhang;Paul E. Bernard;James M. Reuben

  • CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.

    Shimin Hu;Zijun Y. Xu-Monette;Aarthi Balasubramanyam;Ganiraju C. Manyam

  • Aptamers and their applications in nanomedicine.

    Hongguang Sun;Youli Zu

  • Human T cell L-plastin bundles actin filaments in a calcium-dependent manner.

    Yuziro Namba;Masaya Ito;Youli Zu;Katsuya Shigesada

  • Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma

    Catherine M. Bollard;Catherine M. Bollard;Catherine M. Bollard;Tamara Tripic;Conrad Russell Cruz;Gianpietro Dotti;Gianpietro Dotti

  • Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.

    Chi Young Ok;Ling Li;Zijun Y. Xu-Monette;Carlo Visco

  • Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study

    Carlo Visco;Alexander Tzankov;Zijun Y. Xu-Monette;Roberto N. Miranda

  • Aptamers: versatile molecular recognition probes for cancer detection

    Hongguang Sun;Weihong Tan;Youli Zu

  • Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma

    Qing Ye;Zijun Y Xu-Monette;Alexandar Tzankov;Lijuan Deng

  • Erratum: Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the international DLBCL rituximab-CHOP consortium program study (Leukemia (2014) 28 (980) Doi:10.1038/leu.2014.24)

    C. Visco;Y. Li;Z. Y. Xu-Monette;R. N. Miranda

Frequent Co-Authors

Govind Bhagat
Govind Bhagat Columbia University
Eric D. Hsi
Eric D. Hsi Cleveland Clinic
Maurilio Ponzoni
Maurilio Ponzoni Vita-Salute San Raffaele University
Miguel A. Piris
Miguel A. Piris Instituto de Salud Carlos III
Andrés J.M. Ferreri
Andrés J.M. Ferreri Vita-Salute San Raffaele University
L. Jeffrey Medeiros
L. Jeffrey Medeiros The University of Texas MD Anderson Cancer Center
Santiago Montes-Moreno
Santiago Montes-Moreno Instituto de Investigación Marqués de Valdecilla
Yong Li
Yong Li Baylor College of Medicine
Ching-Hsuan Tung
Ching-Hsuan Tung Cornell University
Xiaobo Zhou
Xiaobo Zhou The University of Texas Health Science Center at Houston

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring studies in Biology and Biochemistry opens the door to a diverse range of online degrees and rewarding career options. For those looking to quickly enter a health-related field, programs like the accelerated nutrition degree online provide a flexible and fast-track opportunity to graduation and immediate workforce entry.

If you’re seeking a blend of science and business, consider the cheapest online mba in healthcare management. This degree can help advance your career in hospital administration, pharmaceutical management, or public health leadership, all while staying budget-friendly.

Several graduates transition to fields like medical coding and health information management. Pursuing ccs certification (Certified Coding Specialist) is a pathway that sets you apart for specialized coding roles in clinical settings. Understanding the differences in certification can help you choose the best route for career growth.

Curious about compensation in this fast-growing sector? Learn more about what is medical coding salary and the steps to enter this field with your background in biology and biochemistry.

Best Scientists Citing Youli Zu

Trending Scientists

Recently Published Articles